Cover Image
Market Research Report

Europe Opioids Drug Market Forecast 2019-2027

Published by Inkwood Research Product code 757037
Published Content info 78 Pages
Delivery time: 2-3 business days
Price
Back to Top
Europe Opioids Drug Market Forecast 2019-2027
Published: December 17, 2018 Content info: 78 Pages
Description

KEY FINDINGS

Europe market of opioid drugs is expected to grow at 2.49% CAGR and will reach $XX billion in revenue by 2027. The market trends of Germany, the United Kingdom, France, Italy, Spain & the collective countries from the Rest of Europe are studied for this report.

MARKET INSIGHTS

The growing numbers of opioid crisis are gradually increasing the numbers of lawsuits that are filed against pharmaceutical companies that manufacture and supply opioid drugs and its variants. Overdosage death and widespread addiction caused by opioid use shed a negative impact on its adoption and recommendation by healthcare units. In Europe, the demand for the opioid abuse-deterrent drug is expected to rise mainly because of increasing numbers of cancer patients and the growing aging population demanding for effective pain therapeutics. The Spanish market for opioid drugs is predicted to have rapid growth during the forecast period due to increase prescriptions of a few modified opioid drugs.

COMPETITIVE INSIGHTS

The chief companies who profit the most for the European opioid drugs market are Indivior, Inc., Acura Pharmaceuticals, Inc., Johnson & Johnson, Allergan PLC, BioDelivery Sciences International, Inc., Cipher Pharmaceuticals, Inc., Collegium Pharmaceutical, Inc., Daiichi Sankyo, Inc., Hikma Pharmaceuticals PLC, Insys Therapeutics, Inc., Janssen Pharmaceuticals, Inc., Lannett Co. Inc., Lupin Ltd., Mylan NV, Pfizer, Inc., Purdue Pharma LP, Sanofi-Aventis S.A., Sun Pharmaceutical Industries Limited (Sun Pharma), Egalet Corp. and Teva Pharmaceutical Industries Ltd.

Table of Contents
Product Code: 22727

Table of Contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. OXYCODONE HOLDS THE LARGEST MARKET SHARE IN TERMS OF PRODUCT
    • 3.2.2. ANESTHESIA IS THE MAJORLY USED APPLICATION

4. MARKET DYNAMICS

  • 4.1. MARKET SCOPE & DEFINITION
  • 4.2. MARKET DRIVERS
    • 4.2.1. INCREASING ROAD ACCIDENTS AND SURGICAL PROCEDURES
    • 4.2.2. ESCALATING PALLIATIVE CARE FOR PATIENTS SUFFERING INTENSELY
    • 4.2.3. USAGE OF ABUSE DETERRENT FORMULATIONS TO RESTRICT THE OPIOID ABUSE
    • 4.2.4. GROWING OCCURRENCE OF CHRONIC PAIN
  • 4.3. MARKET RESTRAINTS
    • 4.3.1. MISUSE OF OPIOIDS
    • 4.3.2. STRINGENT REGULATORY FRAMEWORK
  • 4.4. MARKET OPPORTUNITIES
    • 4.4.1. INCREASING USE OF EXTENDED-RELEASE OPIOID FORMULATIONS
    • 4.4.2. WIDE RANGE OF APPLICATIONS OF OPIOIDS IN THE THERAPEUTIC MANAGEMENT
  • 4.5. MARKET CHALLENGES
    • 4.5.1. INCREASING NUMBER OF LAWSUITS CASES AGAINST OPIOIDS MANUFACTURERS
    • 4.5.2. RISING OCCURRENCE OF DEATHS RELATED TO OPIOID OVERDOSE

5. MARKET BY PRODUCTS

  • 5.1. BUPRENORPHINE
  • 5.2. FENTANYL
  • 5.3. HYDROCODONE
  • 5.4. MORPHINE
  • 5.5. OXYCODONE
  • 5.6. TRAMADOL
  • 5.7. OTHER PRODUCTS

6. MARKET BY APPLICATION

  • 6.1. PAIN RELIEF
    • 6.1.1. CANCER PAIN
    • 6.1.2. POSTOPERATIVE PAIN MANAGEMENT
    • 6.1.3. LOW BACK PAIN
    • 6.1.4. ORTHOPEDIC
    • 6.1.5. NEUROPATHIC
    • 6.1.6. FIBROMYALGIA
  • 6.2. ANESTHESIA
  • 6.3. COUGH SUPPRESSION
  • 6.4. DIARRHEA SUPPRESSION
  • 6.5. DEADDICTION

7. KEY ANALYTICS

  • 7.1. PORTER'S FIVE FORCE MODEL
    • 7.1.1. THREAT OF NEW ENTRANTS
    • 7.1.2. THREAT OF SUBSTITUTE
    • 7.1.3. BARGAINING POWER OF SUPPLIERS
    • 7.1.4. BARGAINING POWER OF BUYERS
    • 7.1.5. THREAT OF COMPETITIVE RIVALRY
  • 7.2. PIPELINE ANALYSIS
  • 7.3. INDUSTRY EVENTS IN OPIOID DRUGS MARKET
  • 7.4. TECHNOLOGIES ADVANCEMENT
  • 7.5. OPPORTUNITY MATRIX

8. GEOGRAPHICAL ANALYSIS

  • 8.1. EUROPE
    • 8.1.1. GERMANY
    • 8.1.2. FRANCE
    • 8.1.3. THE UNITED KINGDOM
    • 8.1.4. SPAIN
    • 8.1.5. ITALY
    • 8.1.6. REST OF EUROPE

9. COMPETITIVE LANDSCAPE

  • 9.1. MARKET POSITION ANALYSIS
  • 9.2. COMPANY PROFILES
    • 9.2.1. ACURA PHARMACEUTICALS, INC.
    • 9.2.2. ALLERGAN PLC
    • 9.2.3. BIODELIVERY SCIENCES INTERNATIONAL, INC.
    • 9.2.4. CIPHER PHARMACEUTICALS INC.
    • 9.2.5. COLLEGIUM PHARMACEUTICAL, INC.
    • 9.2.6. DAIICHI SANKYO, INC.
    • 9.2.7. EGALET CORP.
    • 9.2.8. HIKMA PHARMACEUTICALS PLC
    • 9.2.9. INDIVIOR INC.
    • 9.2.10. INSYS THERAPEUTICS, INC.
    • 9.2.11. JANSSEN PHARMACEUTICALS, INC.
    • 9.2.12. JOHNSON & JOHNSON
    • 9.2.13. LANNETT CO. INC.
    • 9.2.14. LUPIN LTD.
    • 9.2.15. MYLAN NV
    • 9.2.16. PFIZER INC.
    • 9.2.17. PURDUE PHARMA LP
    • 9.2.18. SANOFI-AVENTIS S.A.
    • 9.2.19. SUN PHARMACEUTICAL INDUSTRIES LIMITED (SUN PHARMA)
    • 9.2.20. TEVA PHARMACEUTICAL INDUSTRIES LTD.

LIST OF TABLES

  • TABLE 1 EUROPE OPIOIDS DRUG MARKET 2019-2027 ($ MILLION)
  • TABLE 2 ANESTHETIC EFFECTS OF DRUGS AT DIFFERENT OPIOID RECEPTORS
  • TABLE 3 FDA APPROVED OPIOIDS WITH ADF LABELLING
  • TABLE 4 NUMBER OF LAWSUITS CASES SETTLED BY OPIOIDS MANUFACTURING COMPANIES AND PHARMACIES 2015-2027
  • TABLE 5 EUROPE OPIOIDS DRUGS MARKET BY PRODUCTS 2019-2027 ($ MILLION)
  • TABLE 6 EUROPE BUPRENORPHINE MARKET 2019-2027 ($ MILLION)
  • TABLE 7 EUROPE FENTANYL MARKET 2019-2027 ($ MILLION)
  • TABLE 8 EUROPE HYDROCODONE MARKET 2019-2027 ($ MILLION)
  • TABLE 9 EUROPE MORPHINE MARKET 2019-2027 ($ MILLION)
  • TABLE 10 EUROPE OXYCODONE MARKET 2019-2027 ($ MILLION)
  • TABLE 11 EUROPE TRAMADOL MARKET 2019-2027 ($ MILLION)
  • TABLE 12 EUROPE OTHER PRODUCTS MARKET 2019-2027 ($ MILLION)
  • TABLE 13 EUROPE OPIOIDS DRUGS MARKET BY APPLICATION 2019-2027 ($ MILLION)
  • TABLE 14 EUROPE OPIOIDS DRUGS MARKET BY APPLICATION 2019-2027 ($ MILLION)
  • TABLE 15 EUROPE PAIN RELIEF MARKET 2019-2027 ($ MILLION)
  • TABLE 16 EUROPE PAIN RELIEF MARKET BY TYPES 2019-2027 ($ MILLION)
  • TABLE 17 EUROPE CANCER PAIN MARKET 2019-2027 ($ MILLION)
  • TABLE 18 EUROPE POSTOPERATIVE PAIN MANAGEMENT MARKET 2019-2027 ($ MILLION)
  • TABLE 19 EUROPE LOW BACK PAIN MARKET 2019-2027 ($ MILLION)
  • TABLE 20 EUROPE ORTHOPEDIC MARKET 2019-2027 ($ MILLION)
  • TABLE 21 EUROPE NEUROPATHIC MARKET 2019-2027 ($ MILLION)
  • TABLE 22 EUROPE FIBROMYALGIA MARKET 2019-2027 ($ MILLION)
  • TABLE 23 EUROPE ANESTHESIA MARKET 2019-2027 ($ MILLION)
  • TABLE 24 EUROPE COUGH SUPPRESSION MARKET 2019-2027 ($ MILLION)
  • TABLE 25 EUROPE DIARRHEA SUPPRESSION MARKET 2019-2027 ($ MILLION)
  • TABLE 26 EUROPE DEADDICTION MARKET 2019-2027 ($ MILLION)
  • TABLE 27 PIPELINE ANALYSES OF OPIOID DRUGS
  • TABLE 28 EUROPE OPIOIDS DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)

LIST OF FIGURES

  • FIGURE 1 EUROPE OPIOIDS DRUG MARKET 2019-2027 ($ MILLION)
  • FIGURE 2 EUROPE OPIOIDS DRUGS MARKET SHARE BY PRODUCTS 2018 & 2027 (%)
  • FIGURE 3 EUROPE OPIOIDS DRUGS MARKET SHARE BY APPLICATION 2018 & 2027 (%)
  • FIGURE 4 PORTER'S FIVE FORCE MODEL
  • FIGURE 5 EUROPE OPIOIDS DRUGS MARKET REGIONAL OUTLOOK 2018 & 2027 (%)
  • FIGURE 6 GERMANY OPIOIDS DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 7 FRANCE OPIOIDS DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 8 THE UNITED KINGDOM OPIOIDS DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 9 SPAIN OPIOIDS DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 10 ITALY OPIOIDS DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 11 REST OF EUROPE OPIOIDS DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 12 OPIOIDS MARKET POSITION ANALYSIS 2017
Back to Top